Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14556183 | 1.00 | CETP (0.65) | CETPNR1I2 | |
| SCHEMBL2465181 | 0.91 | CETP (0.62) | CETPNR1I2 | |
| SCHEMBL17582685 | 0.86 | CETP (0.65) | CETPNR1I2 | |
| SCHEMBL17582686 | 0.86 | CETP (0.65) | CETPNR1I2 | |
| SCHEMBL14556292 | 0.82 | CETP (0.60) | CETPNR1I2 | |
| SCHEMBL14556293 | 0.82 | CETP (0.60) | CETPNR1I2 | |
| SCHEMBL14556291 | 0.81 | CETP (0.61) | CETPNR1I2 | |
| SCHEMBL2362666 | 0.81 | CETP (0.60) | CETPNR1I2 | |
| SCHEMBL13413428 | 0.80 | CETP (0.61) | CETPNR1I2 | |
| SCHEMBL29786762 | 0.80 | CETP (0.64) | CETPNR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2348859-B1 | PRODRUGS OF OXAZOLIDINONE CETP INHIBITORS | MERCK SHARP & DOHME (US) | 2013-12-04 | — | — | EP | disclosed |
| US-8354454-B2 | Prodrugs of oxazolidinone CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-01-15 | — | — | US | disclosed |
| US-20110218177-A1 | PRODRUGS OF OXAZOLIDINONE CETP INHIBITORS | MERCK SHARP & DOHME LLC | 2011-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110218177-A1 | PRODRUGS OF OXAZOLIDINONE CETP INHIBITORS | CETP, SLCO2B1, OXA1L | CETP 1/4885NR1I2 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.